Zura Bio falls after commencing stock offering

Zura Bio's ZURA.O shares down 4.8% in extended trading to $6.37 after planned equity raise news

Autoimmune and inflammatory diseases firm announces offering of shares and pre-funded warrants; deal size not disclosed

It intends to use net offering proceeds for working capital, advance its pipeline, and general purposes, per the prospectus

Co says its lead product candidate, tibulizumab, being evaluated in mid-stage studies for autoimmune conditions hidradenitis suppurativa and systemic sclerosis

Leerink Partners, Piper Sandler and Cantor Fitzgerald joint bookrunners for offering

Henderson, Nevada-headquartered co has ~73.7 mln shares outstanding, per LSEG data, for nearly $500 mln market cap

ZURA shares on Tues closed up 2.5% at $6.69. Stock up ~28% YTD after more than doubling in 2025

All 8 analysts are bullish including 4 "strong buy" ratings; median PT $15, per LSEG data